- Home
- LMNR vs PACB Comparison
LMNR vs PACB Comparison
Compare LMNR & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMNR
- PACB
- Stock Information
- Founded
- LMNR 1893
- PACB 2000
- Country
- LMNR United States
- PACB United States
- Employees
- LMNR N/A
- PACB N/A
- Industry
- LMNR Farming/Seeds/Milling
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- LMNR Consumer Staples
- PACB Industrials
- Exchange
- LMNR Nasdaq
- PACB Nasdaq
- Market Cap
- LMNR 440.5M
- PACB 364.2M
- IPO Year
- LMNR N/A
- PACB 2010
- Fundamental
- Price
- LMNR $17.73
- PACB $1.13
- Analyst Decision
- LMNR Hold
- PACB Buy
- Analyst Count
- LMNR 1
- PACB 13
- Target Price
- LMNR $23.00
- PACB $2.46
- AVG Volume (30 Days)
- LMNR 75.8K
- PACB 8.3M
- Earning Date
- LMNR 03-12-2025
- PACB 05-08-2025
- Dividend Yield
- LMNR 1.69%
- PACB N/A
- EPS Growth
- LMNR N/A
- PACB N/A
- EPS
- LMNR 0.43
- PACB N/A
- Revenue
- LMNR $186,077,000.00
- PACB $154,014,000.00
- Revenue This Year
- LMNR $6.42
- PACB $7.15
- Revenue Next Year
- LMNR $5.90
- PACB $26.20
- P/E Ratio
- LMNR $41.50
- PACB N/A
- Revenue Growth
- LMNR 2.39
- PACB N/A
- 52 Week Low
- LMNR $17.12
- PACB $1.08
- 52 Week High
- LMNR $29.22
- PACB $3.70
- Technical
- Relative Strength Index (RSI)
- LMNR 28.56
- PACB 35.91
- Support Level
- LMNR $17.38
- PACB $1.08
- Resistance Level
- LMNR $18.40
- PACB $1.36
- Average True Range (ATR)
- LMNR 0.95
- PACB 0.09
- MACD
- LMNR 0.03
- PACB -0.00
- Stochastic Oscillator
- LMNR 14.29
- PACB 17.24
About LMNR Limoneira Co
Limoneira Co is an agribusiness company. The company's operating segments include Fresh Lemons; Lemon Packing; Avocados and Other Agribusiness. It generates maximum revenue from the Fresh Lemons segment.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.